BACKGROUND AND OBJECTIVES: Current grading systems of acute graft-versus-host disease (GVHD) cannot effectively identify patients with poor prognosis at the onset of acute GVHD after allogeneic hematopoietic cell transplantation. DESIGN AND METHODS: In a retrospective analysis, we evaluated the prognostic value of various clinical parameters at the initiation of treatment in 83 patients who developed systemic treatment-requiring acute GVHD after allogeneic hematopoietic cell transplantation. RESULTS: Forty-three of 83 patients (52%) experienced initial treatment failure (40 required secondary treatment due to lack of response and 3 died) and 43 (52%) experienced treatment success, defined as completion of treatment (initial and, if given, secondary) within 100 days. The GVHD-specific survival rate was 65.5%, with 27 deaths due to GVHD-related complications without relapse of underlying malignancies within 1 year. HLA-mismatched transplantation, visceral initiation, and peripheral blood lymphocytopenia ( pound100/mL) were independent variables predicting higher initial treatment failure (Odd ratios (OR)=12.225, 12.036, and 7.481, respectively). The above variables and initial acute GVHD grade III-IV vs. II were independent variables predicting shorter GVHD-specific survival (OR=0.322, 0.247, 0.340, and 0.385, respectively). High-risk disease status, visceral initiation, and hypoalbuminemia ( pound2.8 g/dL) were independent variables predicting lower treatment success (OR=0.221, 0.162, and 0.270, respectively). The predictive value of visceral initiation and lymphocytopenia for GVHD-specific survival was verified in an independent cohort of 58 patients. INTERPRETATION AND CONCLUSIONS: Lymphocytopenia and hypoalbuminemia may be useful baseline prognostic factors for acute GVHD after allogeneic hematopoietic cell transplantation.
BACKGROUND AND OBJECTIVES: Current grading systems of acute graft-versus-host disease (GVHD) cannot effectively identify patients with poor prognosis at the onset of acute GVHD after allogeneic hematopoietic cell transplantation. DESIGN AND METHODS: In a retrospective analysis, we evaluated the prognostic value of various clinical parameters at the initiation of treatment in 83 patients who developed systemic treatment-requiring acute GVHD after allogeneic hematopoietic cell transplantation. RESULTS: Forty-three of 83 patients (52%) experienced initial treatment failure (40 required secondary treatment due to lack of response and 3 died) and 43 (52%) experienced treatment success, defined as completion of treatment (initial and, if given, secondary) within 100 days. The GVHD-specific survival rate was 65.5%, with 27 deaths due to GVHD-related complications without relapse of underlying malignancies within 1 year. HLA-mismatched transplantation, visceral initiation, and peripheral blood lymphocytopenia ( pound100/mL) were independent variables predicting higher initial treatment failure (Odd ratios (OR)=12.225, 12.036, and 7.481, respectively). The above variables and initial acute GVHD grade III-IV vs. II were independent variables predicting shorter GVHD-specific survival (OR=0.322, 0.247, 0.340, and 0.385, respectively). High-risk disease status, visceral initiation, and hypoalbuminemia ( pound2.8 g/dL) were independent variables predicting lower treatment success (OR=0.221, 0.162, and 0.270, respectively). The predictive value of visceral initiation and lymphocytopenia for GVHD-specific survival was verified in an independent cohort of 58 patients. INTERPRETATION AND CONCLUSIONS:Lymphocytopenia and hypoalbuminemia may be useful baseline prognostic factors for acute GVHD after allogeneic hematopoietic cell transplantation.
Authors: Andrew C Harris; James L M Ferrara; Thomas M Braun; Ernst Holler; Takanori Teshima; John E Levine; Sung W Choi; Karin Landfried; Koichi Akashi; Mark Vander Lugt; Daniel R Couriel; Pavan Reddy; Sophie Paczesny Journal: Blood Date: 2012-01-27 Impact factor: 22.113
Authors: Bipin N Savani; Stephan Mielke; Katayoun Rezvani; Aldemar Montero; Agnes S Yong; Laura Wish; Jeannine Superata; Roger Kurlander; Anurag Singh; Richard Childs; A John Barrett Journal: Biol Blood Marrow Transplant Date: 2007-08-24 Impact factor: 5.742
Authors: John M Magenau; Steven C Goldstein; Dan Peltier; Robert J Soiffer; Thomas Braun; Attaphol Pawarode; Mary M Riwes; Maggi Kennel; Joseph H Antin; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Brian L Parkin; Gregory A Yanik; Sung Won Choi; Eli C Lewis; Charles A Dinarello; John Koreth; Pavan Reddy Journal: Blood Date: 2018-02-02 Impact factor: 22.113
Authors: S Fuji; K Takano; T Mori; T Eto; S Taniguchi; K Ohashi; H Sakamaki; Y Morishima; K Kato; K Miyamura; R Suzuki; T Fukuda Journal: Bone Marrow Transplant Date: 2014-08-11 Impact factor: 5.483
Authors: A Shimoni; U Rimon; M Hertz; R Yerushalmi; M Amitai; O Portnoy; L Guranda; A Nagler; S Apter Journal: Br J Radiol Date: 2011-11-29 Impact factor: 3.039
Authors: Katarina Le Blanc; A John Barrett; Marie Schaffer; Hans Hägglund; Per Ljungman; Olle Ringdén; Mats Remberger Journal: Biol Blood Marrow Transplant Date: 2009-09 Impact factor: 5.742
Authors: Jeannine S McCune; Paolo Vicini; David H Salinger; Paul V O'Donnell; Brenda M Sandmaier; Claudio Anasetti; Donald E Mager Journal: Cancer Chemother Pharmacol Date: 2014-11-06 Impact factor: 3.333
Authors: Carrie L Kitko; Sophie Paczesny; Gregory Yanik; Thomas Braun; Dawn Jones; Joel Whitfield; Sung W Choi; Raymond J Hutchinson; James L M Ferrara; John E Levine Journal: Biol Blood Marrow Transplant Date: 2008-07 Impact factor: 5.742